Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $287.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price increased by research analysts at Wells Fargo & Company from $275.00 to $287.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 13.17% from the stock’s current price.

A number of other equities analysts have also recently commented on the stock. HC Wainwright lifted their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. Chardan Capital reissued a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday. Bank of America boosted their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research report on Friday. JPMorgan Chase & Co. boosted their price objective on shares of Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a “neutral” rating in a research report on Tuesday, March 11th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $307.09.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $253.60 on Friday. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company has a 50-day moving average price of $256.25 and a 200 day moving average price of $259.51. The stock has a market cap of $32.83 billion, a PE ratio of -116.87 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares in the company, valued at $3,654,862.41. The trade was a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock worth $19,958,097 in the last 90 days. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Larson Financial Group LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 73 shares during the last quarter. Park Square Financial Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $28,000. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $33,000. OFI Invest Asset Management purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $35,000. Finally, Colonial Trust Co SC purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $35,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.